These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26986753)

  • 21. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
    Bradbury CA; Craig Z; Cook G; Pawlyn C; Cairns DA; Hockaday A; Paterson A; Jenner MW; Jones JR; Drayson MT; Owen RG; Kaiser MF; Gregory WM; Davies FE; Child JA; Morgan GJ; Jackson GH
    Blood; 2020 Aug; 136(9):1091-1104. PubMed ID: 32438407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.
    Singh A; Gajra A
    Cardiovasc Hematol Agents Med Chem; 2011 Jan; 9(1):7-13. PubMed ID: 20874693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence.
    Alexander M; Kirsa S; Mellor JD
    Asia Pac J Clin Oncol; 2012 Dec; 8(4):319-24. PubMed ID: 22897571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
    Menon SP; Rajkumar SV; Lacy M; Falco P; Palumbo A
    Cancer; 2008 Apr; 112(7):1522-8. PubMed ID: 18278812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of thrombosis with lenalidomide and its prevention with aspirin.
    Hirsh J
    Chest; 2007 Jan; 131(1):275-7. PubMed ID: 17218586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.
    Leleu X; Rodon P; Hulin C; Daley L; Dauriac C; Hacini M; Decaux O; Eisemann JC; Fitoussi O; Lioure B; Voillat L; Slama B; Al Jijakli A; Benramdane R; Chaleteix C; Costello R; Thyss A; Mathiot C; Boyle E; Maloisel F; Stoppa AM; Kolb B; Michallet M; Lamblin A; Natta P; Facon T; Elalamy I; Fermand JP; Moreau P
    Thromb Haemost; 2013 Oct; 110(4):844-51. PubMed ID: 23903204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of the venous thrombotic issues associated with multiple myeloma.
    Fotiou D; Gerotziafas G; Kastritis E; Dimopoulos MA; Terpos E
    Expert Rev Hematol; 2016 Jul; 9(7):695-706. PubMed ID: 27232265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspirin in the primary prophylaxis of venous thromboembolism in surgical patients.
    Sahebally SM; Healy D; Walsh SR
    Surgeon; 2015 Dec; 13(6):348-58. PubMed ID: 26071929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update of thrombosis in multiple myeloma.
    Leebeek FW
    Thromb Res; 2016 Apr; 140 Suppl 1():S76-80. PubMed ID: 27067983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial.
    Sayar Z; Czuprynska J; Patel JP; Benjamin R; Roberts LN; Patel RK; Cornelius V; Arya R
    J Thromb Thrombolysis; 2019 Aug; 48(2):315-322. PubMed ID: 31168688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin.
    Kato A; Takano H; Ichikawa A; Koshino M; Igarashi A; Hattori K; Nagata K
    Thromb Res; 2013 Feb; 131(2):140-4. PubMed ID: 23232090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
    Zagouri F; Roussou M; Kastritis E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Kalapanida D; Christoulas D; Migkou M; Terpos E; Dimopoulos MA
    Leuk Lymphoma; 2016 Aug; 57(8):1776-80. PubMed ID: 26916452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Newly diagnosed multiple myeloma: Do we need to propose thromboprophylaxis?].
    Chalayer E; Augeul-Meunier K; Tardy-Poncet B; Cathebras P; Guyotat D; Tardy B
    Rev Med Interne; 2012 Dec; 33(12):693-6. PubMed ID: 23067869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
    Thaler J; Ay C; Pabinger I
    Thromb Haemost; 2012 Dec; 108(6):1042-8. PubMed ID: 22836491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents.
    Santoro M; Romano A; Mancuso S; Siragusa S; DI Raimondo F; Martinelli G; Cerchione C
    Panminerva Med; 2021 Mar; 63(1):1-6. PubMed ID: 32955183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience.
    Soyer N; Patır P; Uysal A; Duran M; Ünal HD; Durusoy R; Tombuloğlu M; Şahin F; Töbü M; Vural F; Saydam G
    Turk J Med Sci; 2018 Aug; 48(4):777-785. PubMed ID: 30119153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
    Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
    Zonder JA; Barlogie B; Durie BG; McCoy J; Crowley J; Hussein MA
    Blood; 2006 Jul; 108(1):403; author reply 404. PubMed ID: 16790586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.